Low powder mass filling of dry powder inhalation formulations

Drug Development and Industrial Pharmacy

Volumn 37, Issue 1, 2011, Pages 24-32

  Eskandar, Fadi ^a   Lejeune, Morgane ^a   Edge, Stephen ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Filling; Fine particle fraction; Inhalation; Lactose; Low mass

Indexed keywords

EXCIPIENT; LACTOSE;

AEROSOL; ARTICLE; CAPSULE FILLING; DRY POWDER; LABORATORY; PERFORMANCE; PHYSICAL CHEMISTRY; POWDER INHALER; TECHNOLOGY;

ADMINISTRATION, INHALATION; CHEMISTRY, PHARMACEUTICAL; DRUG COMPOUNDING; DRY POWDER INHALERS; EXCIPIENTS; LACTOSE; PARTICLE SIZE; POWDERS;

EID: 78650009830     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2010.489561     Document Type: Article

References (21)

1. Byron B, Patton J. (1994). Drug delivery via the respiratory tract. J Aerosol Med, 7:49-75.
2. Barnes P, Grundstein M, Leff A, Woolcock A. (1997). Asthma. Philadelphia, PA: Lippincott-Raven.
3. Brown J, Zeman K, Benett W. (2001). Regional deposition of coarse particles and ventilation distribution in healthy subjects and patients with cystic fibrosis. J Aerosol Med, 14:443-54.
4. Stockley J, Rennad S, Rabe K, Celli B. (2007). Chronic obstructive pulmonary diseases. Oxford, UK: Blackwell.
5. Prime D, Atkins P, Slater A, Sumby B. (1997). Review of dry powder inhalers. Adv Drug Deliv Rev, 26:51-8.
6. Dolovich M, Ahrens R, Hess D, Anderson P, Dhand R, Rau J, et al. (2005). Device selection and outcomes of aerosol therapy: Evidences based guidelines. Chest, 127:335-71.
7. Newman S, Busse W. (2002). Evolution of dry powder inhaler design: Formulation and performance. Respir Med, 96:293-304.
8. Newman, S. (2004). Dry powder inhalers for optimal drug delivery. Expert Opin Biol Ther, 4:23-33.
9. Newman S, Peart J. (2009). Dry powder inhalers. In: Newman S, ed. Respiratory drug delivery essential theory and practice. Richmond, VA: Respiratory Drug Delivery, 257-307.
10. Daniher D, Zhu J. (2008). Dry powder platform for pulmonary drug delivery. Particuology, 6:225-38.
11. Lippmann M, Albert R. (1969). The effect of particle size on the regional deposition of inhaled aerosols in the human respiratory tract. Am Ind Hyg Assoc J, 30:257-75.
12. Lalor C, Hickey A. (1998). Pharmaceutical aerosols for delivery of drugs to the lung. In: Colbeck I, ed. Physical and chemical properties of aerosols. London: Blackie Academic and Professional, 391-428.
13. Telko M, Hickey AJ. (2005). Dry powder inhaler formulations. Respir Care, 50:1209-27.
14. Islam N, Gladki E. (2008). Dry powder inhalers (DPIs)-a review of device reliability and innovation. Int J Pharm, 360:1-11.
15. Jones M, Price R. (2006). The influence of fine excipient particles on the performance of carrier-based dry powder inhalation formulations. Pharm Res, 23:1665-74.
16. European Pharmacopoiea. (2009). Bulk and tapped density of powders. 6th ed. 2.09.34. Strasbourg, France: Council of Europe. http://online.pheur.org [accessed May 6, 2010].
17. Carr RL. (1965). Evaluating the flow properties of solids-classifying flow properties of solids. Chem Eng, 72:163-8.
18. United States Pharmacopoeia 32 National Formulary 27, 2nd supp. (2010). Powder flow <1174>. Rockville, MD: The United States Pharmacopoeial Convention, Inc. www.uspnf.com [accessed May 6, 2010].
19. Aakerberg V, Thalberg K. (2005). Dosing study with Omnidose powder dosing system. Proc. drug delivery to the lung 16, Edinburgh, UK, December 7-9.
20. Markefka P, Steckel H. (2002). Assessment of low levels of amorphous content in lactose by DVS and isothermal microcalorimetry. Arch Pharm Med Chem, 10:335.
21. European Pharmacopoiea. (2010). Preparations for inhalation: Aerodynamic assessment of fine particles. 6th ed., 7th supp., 2.9.18. Strasbourg, France: Council of Europe. http:// online.pheur.org [accessed May 6, 2010].